“We have one of the World’s Most Advanced Functional HIV Cures under development”

Abivax has recently announced that it’s likely that its most advanced program in hepatitis B will fail its Phase III trials. That’s really bad news for the company, and stocks have plummeted by around 50%. But what does this really mean for the future of Abivax? To find out, I had a chat with the company’s CEO Hartmut Ehrlich and its CMO Jean-Marc Steens…

 

Abivax is one of the high-profile Biotechs in Paris. With a pipeline with candidates for hepatitis B and HIV, it raised €57Mduring its IPO on the Euronext Paris – the biggest ever in French Biotech.

Read more here

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41

More articles in French

Click here